(April 1, 2015) A study published in Cancer Epidemiology, Biomarkers and Prevention looks at ovarian cancer risk in the general population. In U.S. women, lifetime risk of ovarian cancer is 1.37%, but some women are at a substantially lower or higher ovarian cancer risk due to both genetic and lifestyle factors. Leigh Pierce, PhD and … Continued
Angelina Jolie Pitt recently announced that she has had her ovaries and fallopian tubes removed in order to reduce her risk of ovarian cancer. Ms. Jolie Pitt had previous shared that she has a mutation in the BRCA gene, which increases her risk of breast and ovarian cancers. The Alliance received many calls and requests … Continued
(March 27, 2015) According to research published this week in the Journal of Clinical Oncology, intraperitoneal (IP) chemotherapy is associated with a long-term survival advantage in ovarian cancer. The advantage of IP over intravenous chemotherapy extends beyond 10 years, and IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number … Continued
The Ovarian Cancer Alliance of Greater Cincinnati (OCAGC) became a Partner Member of the Alliance in October 2010. “It’s been a very positive partnership,” says Martha Farr, an ovarian cancer survivor and co-chair of OCAGC’s Board of Trustees. The group started almost a decade ago, hosting an annual walk to raise awareness. Eventually, the volunteers … Continued
(March 20, 2015) This excellent, accessible piece in Mosaic Magazine, “Decisions on a Knife-Edge,” explores the difficult choices high-risk women face when considering how to decrease their chances of developing ovarian cancer. Removing only the fallopian tubes will avoid forcing a woman into early menopause, which is an appealing option for many women. Yet it’s not … Continued
(March 10, 2015) An algorithm developed at MD Anderson Cancer Center in Houston has dramatically increased complete resection rates in advanced ovarian cancer, giving patients the best possible chance of survival. The work was funded in part by an OCRF research grant to Anil Sood, MD. The results are summarized in an article in Nature … Continued
Gynecologic Cancer Patients to Receive New Support in Baltimore, MD and Portland, OR WEST CHESTER, Pa (February 23, 2015) —Ovarian Cancer Research Fund (OCRF) and QVC® today announced two new Woman to Woman grant recipients: Mercy Medical Center in Baltimore, MD, and Oregon Health and Science University in Portland, OR. The new sites are part … Continued
(February 17, 2015) OCRF-funded researchers at The Wistar Institute have identified a new therapeutic target in clear cell ovarian cancer, paving the way for what could be the first effective targeted therapy of its kind for the disease. The findings were published online by the journal Nature Medicine. The research was made possible in part … Continued
(February 13, 2015) University of Chicago Medicine researchers, including OCRF grantee and Scientific Advisory Committee member Ernst Lengyel, MD, PhD, have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis. Their three-dimensional cell-culture system, adapted for high-throughput screening, has … Continued
Total investment in the field now over $65 million New York, NY February 11, 2015 — To conclude Ovarian Cancer Research Fund’s 20th anniversary year, $6.453 million has been awarded in scientific research grants for ovarian cancer and program grants to support gynecologic cancer patients. This brings OCRF’s total investment in research and related educational … Continued
(February 11, 2015) Ovarian Cancer Research Fund has announced that $6.1 million has been awarded in scientific research grants for ovarian cancer. This brings OCRF’s total investment in research and related educational and support initiatives to nearly $70 million. The twenty new OCRF research grants have been awarded to top scientists at fourteen leading medical centers across … Continued
(February 4, 2014) In research published last October in Clinical Cancer Research, a team of OCRF-funded investigators showed that a novel therapy can resentisize ovarian cancer to chemotherapy. The work was led by Dr. Kenneth Nephew, who was funded through an OCRF Program Project Development Grant. The development of resistance to chemotherapy in ovarian cancer … Continued
Get email updates about research news, action alerts, and ways to join the fight.
